|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lahiri A, Maji A, Potdar PD, Singh N,
Parikh P, Bisht B, Mukherjee A and Paul MK: Lung cancer
immunotherapy: progress, pitfalls, and promises. Mol Cancer.
22:402023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi J, Hua X, Zhu B, Ravichandran S, Wang
M, Nguyen C, Brodie SA, Palleschi A, Alloisio M, Pariscenti G, et
al: Somatic genomics and clinical features of lung adenocarcinoma:
A retrospective study. PLoS Med. 13:e10021622016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ortega MA, Pekarek L, Navarro F,
Fraile-Martínez O, García-Montero C, Álvarez-Mon MÁ, Diez-Pedrero
R, Boyano-Adánez MDC, Guijarro LG, Barrena-Blázquez S, et al:
Updated views in targeted therapy in the patient with non-small
cell lung cancer. J Pers Med. 13:1672023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Byun J, Schwartz AG, Lusk C, Wenzlaff AS,
de Andrade M, Mandal D, Gaba C, Yang P, You M, Kupert EY, et al:
Genome-wide association study of familial lung cancer.
Carcinogenesis. 39:1135–1140. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schreiber RD, Old LJ and Smyth MJ: Cancer
immunoediting: Integrating immunity's roles in cancer suppression
and promotion. Science. 331:1565–1570. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Joyce JA and Fearon DT: T cell exclusion,
immune privilege, and the tumor microenvironment. Science.
348:74–80. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karasaki T, Nagayama K, Kuwano H, Nitadori
JI, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y,
Kashiwabara K, et al: An immunogram for the cancer-immunity cycle:
Towards personalized immunotherapy of lung cancer. J Thorac Oncol.
12:791–803. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liede A, Hernandez RK, Wade SW, Bo R,
Nussbaum NC, Ahern E, Dougall WC and Smyth MJ: An observational
study of concomitant immunotherapies and denosumab in patients with
advanced melanoma or lung cancer. Oncoimmunology. 7:e14803012018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mahalingam P and Newsom-Davis T: Cancer
immunotherapy and the management of side effects. Clin Med (Lond).
23:56–60. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo W: Nasopharyngeal carcinoma ecology
theory: Cancer as multidimensional spatiotemporal ‘unity of ecology
and evolution’ pathological ecosystem. Theranostics. 13:1607–1631.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang Y, Yu Y and Lu S: Effectiveness of
PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness
and challenge. Sci China Life Sci. 63:1499–1514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang S, Zeng Z, Liu Y, Huang J, Long J,
Wang Y, Peng X, Hu Z and Ouyang Y: Prognostic landscape of
tumor-infiltrating immune cells and immune-related genes in the
tumor microenvironment of gastric cancer. Aging (Albany NY).
12:17958–17975. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heagerty PJ, Lumley T and Pepe MS:
Time-dependent ROC curves for censored survival data and a
diagnostic marker. Biometrics. 56:337–344. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li S, Zhu R, Li D, Li N and Zhu X:
Prognostic factors of oligometastatic non-small cell lung cancer: A
meta-analysis. J Thorac Dis. 10:3701–3713. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ortega MA, Navarro F, Pekarek L,
Fraile-Martínez O, García-Montero C, Saez MA, Arroyo M, Monserrat J
and Alvarez-Mon M: Exploring histopathological and serum biomarkers
in lung adenocarcinoma: Clinical applications and translational
opportunities (review). Int J Oncol. 61:1542022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leduc C, Antoni D, Charloux A, Falcoz PE
and Quoix E: Comorbidities in the management of patients with lung
cancer. Eur Respir J. 49:16017212017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fan T, Lu J, Niu D, Zhang Y, Wang B, Zhang
B, Zhang Z, He X, Peng N, Li B, et al: Immune and non-immune cell
subtypes identify novel targets for prognostic and therapeutic
strategy: A study based on intratumoral heterogenicity analysis of
multicenter scRNA-seq datasets in lung adenocarcinoma. Front
Immunol. 13:10461212022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Airoldi I, Di Carlo E, Cocco C, Caci E,
Cilli M, Sorrentino C, Sozzi G, Ferrini S, Rosini S, Bertolini G,
et al: IL-12 can target human lung adenocarcinoma cells and normal
bronchial epithelial cells surrounding tumor lesions. PLoS One.
4:e61192009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang Q, Duan L, Qian X, Fan J, Lv Z,
Zhang X, Han J, Wu F, Guo M, Hu G, et al: IL-17 promotes angiogenic
factors IL-6, IL-8, and Vegf production via Stat1 in lung
adenocarcinoma. Sci Rep. 6:365512016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suzuki K, Kadota K, Sima CS, Nitadori J,
Rusch VW, Travis WD, Sadelain M and Adusumilli PS: Clinical impact
of immune microenvironment in stage I lung adenocarcinoma: Tumor
interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3
ratio are independent predictors of recurrence. J Clin Oncol.
31:490–498. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Domagala-Kulawik J, Kwiecien I, Pankowski
J, Pasieka-Lis M, Wolosz D and Zielinski M: Elevated Foxp3/CD8
ratio in lung adenocarcinoma metastatic lymph nodes resected by
transcervical extended mediastinal lymphadenectomy. Biomed Res Int.
2017:51850342017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma C, Li F, Wang Z and Luo H: A novel
immune-related gene signature predicts prognosis of lung
adenocarcinoma. Biomed Res Int. 2022:49958742022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu X, Zhu J, Liu W, Jin M, Xiong M and Hu
K: A novel prognostic and predictive signature for lung
adenocarcinoma derived from combined hypoxia and infiltrating
immune cell-related genes in TCGA patients. Int J Gen Med.
14:10467–10481. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang D, Ma X and Song P: A prognostic
model of non small cell lung cancer based on TCGA and ImmPort
databases. Sci Rep. 12:4372022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun L, Zhang Z, Yao Y, Li WY and Gu J:
Analysis of expression differences of immune genes in non-small
cell lung cancer based on TCGA and ImmPort data sets and the
application of a prognostic model. Ann Transl Med. 8:5502020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun S, Guo W, Wang Z, Wang X, Zhang G,
Zhang H, Li R, Gao Y, Qiu B, Tan F, et al: Development and
validation of an immune-related prognostic signature in lung
adenocarcinoma. Cancer Med. 9:5960–5975. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qi C, Ma J, Sun J, Wu X and Ding J: The
role of molecular subtypes and immune infiltration characteristics
based on disulfidptosis-associated genes in lung adenocarcinoma.
Aging (Albany NY). 15:5075–5095. 2023.PubMed/NCBI
|
|
32
|
Babini E, Bertini I, Borsi V, Calderone V,
Hu X, Luchinat C and Parigi G: Structural characterization of human
S100A16, a low-affinity calcium binder. J Biol Inorg Chem.
16:243–256. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Basnet S, Vallenari EM, Maharjan U, Sharma
S, Schreurs O and Sapkota D: An update on S100A16 in human cancer.
Biomolecules. 13:10702023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen D, Luo L and Liang C: Aberrant
S100A16 expression might be an independent prognostic indicator of
unfavorable survival in non-small cell lung adenocarcinoma. PLoS
One. 13:e01974022018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun X, Wang T, Zhang C, Ning K, Guan ZR,
Chen SX, Hong TT and Hua D: S100A16 is a prognostic marker for
colorectal cancer. J Surg Oncol. 117:275–283. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bassi DE, Mahloogi H, Al-Saleem L, Lopez
De Cicco R, Ridge JA and Klein-Szanto AJ: Elevated furin expression
in aggressive human head and neck tumors and tumor cell lines. Mol
Carcinog. 31:224–232. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Braun E and Sauter D: Furin-mediated
protein processing in infectious diseases and cancer. Clin Transl
Immunology. 8:e10732019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Babina IS and Turner NC: Advances and
challenges in targeting FGFR signalling in cancer. Nat Rev Cancer.
17:318–332. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Im JH, Buzzelli JN, Jones K, Franchini F,
Gordon-Weeks A, Markelc B, Chen J, Kim J, Cao Y and Muschel RJ:
FGF2 alters macrophage polarization, tumour immunity and growth and
can be targeted during radiotherapy. Nat Commun. 11:40642020.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gong X, Yi J, Carmon KS, Crumbley CA,
Xiong W, Thomas A, Fan X, Guo S, An Z, Chang JT and Liu QJ:
Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung
adenocarcinomas promotes tumor aggressiveness. Oncogene.
34:4692–4701. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Luo J, Yang Z, Ma Y, Yue Z, Lin H, Qu G,
Huang J, Dai W, Li C, Zheng C, et al: LGR4 is a receptor for RANKL
and negatively regulates osteoclast differentiation and bone
resorption. Nat Med. 22:539–546. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Glinka A, Dolde C, Kirsch N, Huang YL,
Kazanskaya O, Ingelfinger D, Boutros M, Cruciat CM and Niehrs C:
LGR4 and LGR5 are R-spondin receptors mediating Wnt/β-catenin and
Wnt/PCP signalling. EMBO Rep. 12:1055–1061. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ruffner H, Sprunger J, Charlat O,
Leighton-Davies J, Grosshans B, Salathe A, Zietzling S, Beck V,
Therier M, Isken A, et al: R-Spondin potentiates Wnt/β-catenin
signaling through orphan receptors LGR4 and LGR5. PLoS One.
7:e409762012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ono T, Hayashi M, Sasaki F and Nakashima
T: RANKL biology: Bone metabolism, the immune system, and beyond.
Inflamm Regen. 40:22020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shang WQ, Li H, Liu LB, Chang KK and Yu
JJ, Xie F, Li MQ and Yu JJ: RANKL/RANK interaction promotes the
growth of cervical cancer cells by strengthening the dialogue
between cervical cancer cells and regulation of IL-8 secretion.
Oncol Rep. 34:3007–3016. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Szilasi M, Buglyo A, Treszl A, Kiss L,
Schally AV and Halmos G: Gene expression of vasoactive intestinal
peptide receptors in human lung cancer. Int J Oncol. 39:1019–1024.
2011.PubMed/NCBI
|
|
47
|
Moody TW, Leyton J, Chan D, Brenneman DC,
Fridkin M, Gelber E, Levy A and Gozes I: VIP receptor antagonists
and chemotherapeutic drugs inhibit the growth of breast cancer
cells. Breast Cancer Res Treat. 68:55–64. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yassin MA, Datiko DG, Tulloch O, Markos P,
Aschalew M, Shargie EB, Dangisso MH, Komatsu R, Sahu S, Blok L, et
al: Innovative community-based approaches doubled tuberculosis case
notification and improve treatment outcome in Southern Ethiopia.
PLoS One. 8:e631742013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao L, Yu Z and Zhao B: Mechanism of
VIPR1 gene regulating human lung adenocarcinoma H1299 cells. Med
Oncol. 36:912019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tong Z, Wang X, Liu H, Ding J, Chu Y and
Zhou X: The relationship between tumor infiltrating immune cells
and the prognosis of patients with lung adenocarcinoma. J Thorac
Dis. 15:600–610. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Aras S and Zaidi MR: TAMeless traitors:
Macrophages in cancer progression and metastasis. Br J Cancer.
117:1583–1591. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wolf D, Sopper S, Pircher A, Gastl G and
Wolf AM: Treg(s) in cancer: Friends or foe? J Cell Physiol.
230:2598–2605. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Platonova S, Cherfils-Vicini J, Damotte D,
Crozet L, Vieillard V, Validire P, André P, Dieu-Nosjean MC,
Alifano M, Régnard JF, et al: Profound coordinated alterations of
intratumoral NK cell phenotype and function in lung carcinoma.
Cancer Res. 71:5412–5422. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yuan D, Koh CY and Wilder JA: Interactions
between B lymphocytes and NK cells. FASEB J. 8:1012–1018. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Garaud S, Buisseret L, Solinas C,
Gu-Trantien C, de Wind A, Van den Eynden G, Naveaux C, Lodewyckx
JN, Boisson A, Duvillier H, et al: Tumor infiltrating B-cells
signal functional humoral immune responses in breast cancer. JCI
Insight. 5:e1296412019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tsou P, Katayama H, Ostrin EJ and Hanash
SM: The emerging role of B cells in tumor immunity. Cancer Res.
76:5597–5601. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tian J, Fu C, Peng Q, Yang J, Fan X, Zeng
X, Qing W and Wu Y: Construction of immune cell infiltration score
model to assess prognostic ability of tumor immune environment in
lung adenocarcinoma. Am J Transl Res. 15:1730–1743. 2023.PubMed/NCBI
|
|
58
|
Chen C, Huang H and Wu CH: Protein
bioinformatics databases and resources. Methods Mol Biol. 694:3–24.
2011. View Article : Google Scholar : PubMed/NCBI
|
